CSIMarket Company Name, Ticker, Competitors, else..
 
Onkure Therapeutics Inc   (NASDAQ: OKUR)
 
Price: $3.5400 $-0.02 -0.562%
Day's High: $3.6649999618530273 Week Perf: -7.57 %
Day's Low: $ 3.41 30 Day Perf: -13.66 %
Volume (M): 127,371 52 Wk High: $ 5.38
Volume (M$): $ 0 52 Wk Avg: $3.49
Open: $3.41 52 Wk Low: $2.23



 Market Capitalization (Millions $) 177
 Shares Outstanding (Millions) 50
 Employees 45
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) 109
 Capital Exp. (TTM) (Millions $) 0

Business Description


OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines targeting specific mutations involved in cancers and other diseases. Its lead product candidate, OKI-219, is a selective inhibitor of the PI3Kα H1047R mutation designed to spare the wild-type enzyme. OKI-219 is currently in clinical trials for breast cancer and is being developed as a backbone therapy for PI3Kα H1047R-driven diseases, including advanced breast cancer subtypes.


   Company Address: 6707 Winchester Circle, Suite 400 Boulder 80301 CO
   Company Phone Number: 307-2892   Stock Exchange / Ticker: NASDAQ OKUR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARTL        817.02% 
BFRG   -14.01%    
INSM        1.8% 
LPCN        9.53% 
RARE        0.34% 
TRDA        4.29% 
• View Complete Report
   



Clinical Study

Navigating the Pharmaceutical Landscape Analyzing OnKure Therapeutics’ Pivotal Trial Results Against Competitive Ma...

Published Mon, Dec 30 2024 9:06 AM UTC

OnKure Therapeutics Inc. has recently announced encouraging preliminary data from its first-in-human trial, PIKture-01, evaluating its investigational therapeutic agent, OKI-219. While these findings indicate favorable safety and tolerability profiles for OKI-219, the company faces a challenging market environment characterized by diminishing revenues and net losses, contras...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 93.80
Price to Sales (Expected) -
Price to Book 1.03
PEG (TTM) -

Financial Strength Current
Quick Ratio 28.04
Working Capital Ratio 28.3
Leverage Ratio (MRQ) 0.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.51 $
Revenues (TTM) 0.04 $
Cash Flow (TTM) 2.18 $
Cash 3.74 $
Book Value 3.45 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,304,556
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.